hotspot -WSS

hotspot

author：hotspot 2025-10-01 15:39:52 - browse：11446

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Psilocybin's anti

explore

WSS

Why you get paid to donate plasma but not blood

CDC advisory panel says seniors 'may' get RSV vaccine

House passes resolution saying Israel isn't a 'racist or apartheid state'

How a symptom of dementia informs our understanding of creativity

Why more medical students aren't specializing in primary care

Flagship, Pfizer team up in deal worth up to $7 billion

focus

hotspot

explore

Psychedelics group wrestles with new pharma identity

What do new weight loss drugs mean for bariatric surgery?

BioMarin wins approval for gene therapy to treat hemophilia A

NYU Langone launches private ChatGPT for its health care data

Alkermes shareholders re

How Long Island became the ‘eugenics capital of the world’

In age of alternative facts, a scholarly course on calling out crap

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

BioMarin wins approval for gene therapy to treat hemophilia A

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

leisure time

Biden administration sends mixed signals on US soldier who crossed into North Korea

Johnson & Johnson sues to stop Medicare negotiation

Study: Hearing aids may slow cognitive decline in those at risk

2024 GOP presidential candidates spar over abortion in debate

How a symptom of dementia informs our understanding of creativity

Neuroscience startup Neumora files for IPO

explore

explore

explore

hotspot